Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines

Hazan‐Halevy, Inbal; Landesman-Milo, Dalit; Rosenblum, Daniel; Mizrahy, Shoshy; Ng, Brandon D.; Peer, Dan

doi:10.1016/j.jconrel.2016.07.052

Cited by 23 publications

(14 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, due to the fact that leukocytes are notoriously hard to transfect and are spread not only in peripheral blood but also in the bone marrow, lymph nodes, lymphatic organs, and other organs, there is an unmet need for developing designated delivery strategies to leukocytes. 25 …”

Section: Relevance Of Tumor Targets Used In Nanomedicinementioning

confidence: 99%

Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions

Barenholz²,

et al. 2017

Self Cite

View full text Add to dashboard Cite

Remarkable progress has recently been made in the synthesis and characterization of engineered nanoparticles for imaging and treatment of cancers, resulting in several promising candidates in clinical trials. Despite these advances, clinical applications of nanoparticle-based therapeutic/imaging agents remain limited by biological, immunological, and translational barriers. In order to overcome the existing status quo in drug delivery, there is a need for open and frank discussion in the nanomedicine community on what is needed to make qualitative leaps toward translation. In this Nano Focus, we present the main discussion topics and conclusions from a recent workshop: “Mechanisms and Barriers in Nanomedicine”. The focus of this informal meeting was on biological, toxicological, immunological, and translational aspects of nanomedicine and approaches to move the field forward productively. We believe that these topics reflect the most important issues in cancer nanomedicine.

show abstract

Section: Relevance Of Tumor Targets Used In Nanomedicinementioning

confidence: 99%

Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions

Barenholz²,

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Liposomes are spherical, self-closed structures formed by one or several concentric lipid bilayers with an aqueous phase inside and between different shells of multilayered particles. 55 To date, more than 13 liposomal formulations have been approved by the FDA, due to their multiple benefits. Liposomal formulations encapsulating siRNA manage to overcome the limitations of antibody-protamine fusion protein and apt-siRNA fusion systems, as they manage to increase the amount of payloads and simplify the preparation procedures.…”

Section: Supramolecular Nanocarriersmentioning

confidence: 99%

Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes

et al. 2017

Self Cite

View full text Add to dashboard Cite

RNAi-based therapy holds great promise, as it can be utilized for the treatment of multiple conditions in an accurate manner via sequence-specific manipulation of gene expression. To date, RNAi therapeutics have advanced into clinical trials for liver diseases and solid tumors; however, delivery of RNAi to leukocytes in general and to lymphocytes in particular remains a challenge. Lymphocytes are notoriously hard to transduce with RNAi payloads and are disseminated throughout the body, often located in deep tissues; therefore, developing an efficient systemic delivery system directed to lymphocytes is not a trivial task. Successful manipulation of lymphocyte function with RNAi possesses immense therapeutic potential, as it will enable researchers to resolve lymphocyte-implicated diseases such as inflammation, autoimmunity, transplant rejection, viral infections, and blood cancers. This potential has propelled the development of novel targeted delivery systems relying on the accumulating research knowledge from multiple disciplines, including materials science and engineering, immunology, and genetics. Here, we will discuss the recent progress in non-viral delivery strategies of RNAi payloads to lymphocytes. Special emphasis will be made on the challenges and potential opportunities in manipulating lymphocyte function with RNAi. These approaches might ultimately become a novel therapeutic modality to treat leukocyte-related diseases.

show abstract

“…Systemic administration of inhibitory oligonucleotides molecules for the manipulation of gene expression in lymphocytes has great potential to facilitate the development of an oligonucleotide-based therapy platform for lymphoid blood cancer. However, lymphocytes are among the most difficult targets for oligonucleotide delivery, as they are resistant to conventional transfection reagents and are dispersed throughout the body, making it difficult to locate or successfully distribute oligonucleotide payloads via systemic administration [6].…”

Section: Introductionmentioning

confidence: 99%

Drug Vectoring Systems to Target Drug Delivery Using Nanotechnologies

Pérez-Surio

Alcacera-Lopez

2018

CNANOM

View full text Add to dashboard Cite

Background: The development of nanostructures (nanoparticles and nanocapsules) is one of the most important pipelines of research of pharmaceutical technology. Methods: These nanotechnology pharmaceuticals allow the vectorization of drugs to tissues or cells target, allowing thus actions more specific and therapeutically active directed by molecules. Results: The use of molecules with an affinity for membrane receptors expressed in specific excess in tumor cells, monoclonal antibodies, or proteins, among others, is common for this purpose. In addition, these nanosystems allow to deliver drugs that could be the basis of the pharmacological treatment of many disorders of genetic origin in the future: biomolecules. Conclusion: The future scope of drug vectoring systems to target drug delivery using nanotechnologies can increase the control of pharmacokinetic parameters of chemotherapeutic agents.

show abstract

Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines

Cited by 23 publications

References 53 publications

Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions

Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions

Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes

Drug Vectoring Systems to Target Drug Delivery Using Nanotechnologies

Contact Info

Product

Resources

About